Skip to main content

Stock futures were higher Friday, putting equities on track to close out with the best monthly gain in four years. 

S&P 500 futures rose 0.13%, Dow Jones Industrial Average futures were up 0.1%, and Nasdaq futures rose 0.13%. 

Benchmark indexes have rallied in October as China and the European Central Bank committed to do whatever it takes to reinvigorate flagging growth. Markets in the U.S. rallied on Wednesday after the Federal Reserve held rates steady. However, a potential December rate hike was left in play. Investors had hoped the Fed would provide further clarification on how likely a rate hike this year might be.

Consumer spending rose in the U.S. in September at the slowest pace this year as consumers spent less on gasoline. Personal spending increased 0.1% over the month, according to the Commerce Department, half the increase economists had expected. Consumers have also become more conservative in recent weeks as the global market looked to be on shakier ground and the U.S. labor market showed signs of weakness. Personal income rose 0.1%, its slowest pace since March, compared to an expected 0.2% increase. 

Anheuser-Busch (BUD) - Get Anheuser-Busch Inbev SA Sponsored ADR (Belgium) Report shares were on watch after the beer company raised its sales forecast for the year on stronger demand for premium lager. The company is currently planning to buy its rival SABMiller (SBMRY) in what will be a record deal for the beer industry.

Exxon Mobil (XOM) - Get Exxon Mobil Corporation Report shares rose 1% after the oil company beat earnings and sales forecasts despite a sharp decline in revenue. Net income of $1.01 a share beat estimates by 12 cents, while revenue of $67.34 billion came in $4 billion above estimates. Sales slumped nearly 40% on tumbling commodity prices.

Scroll to Continue

TheStreet Recommends

Colgate-Palmolive (CL) - Get Colgate-Palmolive Company Report reported a drop in quarterly sales due to a stronger U.S. dollar. Total revenue fell nearly 9% to $4 billion with the impact of foreign exchange cutting into the top-line by 13 percentage points. Organic sales increased 5% and were up 8% in emerging markets. 

AbbVie (ABBV) - Get AbbVie Inc. Report climbed more than 5% in premarket trading after reporting an 18% jump in total revenue. The drugmaker narrowed its full-year earnings guidance to $4.26 to $4.28 a share from a previous range of $4.10 to $4.30.  

Starbucks (SBUX) - Get Starbucks Corporation Report shares fell 2% in premarket trading after the coffee chain provided a weaker-than-expected forecast for the holiday season. The company expects earnings in the current quarter of between 44 cents and 45 cents a share, below estimates of 47 cents. 

LinkedIn (LNKD) jumped 10% after a better-than-expected third quarter and fourth-quarter projections above estimates. The professional social network reported a 37% increase in sales over its recent quarter after the company gained traction in its expansion in China. 

Western Union (WU) - Get Western Union Company (The) Report added 3% as the company continued to grow in U.S. outbound money transfers. The company said sales fell 2.9% to $1.4 billion, though climbed 3% when the effect of a stronger U.S. dollar was stripped away. 

SolarCity (SCTY) shares slumped more than 18% after losses widened to $234 million over its recent quarter from just $70 million in the year-ago period. An adjusted loss of $2.10 a share was wider than an expected $1.95 loss. Revenue climbed on increased installations of its alternative-energy systems. 

Nu Skin (NUS) - Get Nu Skin Enterprises Inc. Report climbed more than 2% after doubling its stock buyback program. The company's board approved plans to increase the program to $500 million from $260 million. 

Valeant (VRX) slumped 5% in premarket trading after Express Scripts (ESRX)  and CVS Health (CVS) - Get CVS Health Corporation Report eliminated the drugmaker's Philidor partner pharmacy from its network. Valeant has since announced it is cutting ties with the specialty pharmacy as well. Valeant has been under pressure since last week when a Citron Research report accused it of using the pharmacy to create fake sales.